Abstract
Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation. © 2014, American Society for Microbiology.
Cite
CITATION STYLE
Jensen, R. H., Justesen, U. S., Rewes, A., Perlin, D. S., & Arendrup, M. C. (2014). Echinocandin failure case due to a previously unreported fks1 mutation in candida krusei. Antimicrobial Agents and Chemotherapy, 58(6), 3550–3552. https://doi.org/10.1128/AAC.02367-14
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.